Elevated frequencies of melanoma infiltrating CD8+ T cells in good responders corroborates previous studies that have demonstrated that increased cell infiltration is associated with beneficial clinical outcomes of patients in response to anti-PD1 therapy [24]. The gene discussed is CD8A; the disease is melanoma.